7210 Wareham Drive, Tampa, FL 33647
July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield […]
Nearly all patients quit weight loss shots within two years, study finds Read More »
June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the
Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »
June 11, 2024 Kroger Health’s The Little Clinic LLC is announcing a renewed approach to its weight management program, offering a holistic and personalized approach to professional medical support and education. When medically appropriate, patients will be able to explore medical treatment, including GLP-1s such as Wegovy, Zepabound and others as part of their weight
Kroger’s Little Clinics Adds GLP-1 Drugs To Its Weight Loss Program Read More »
May 22, 2024 A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association. The study was conducted by Blue Health Intelligence and is based on national pharmacy and medical claims data from
Most weight loss drug users quit before seeing benefits Read More »
May 20, 2024 Medifast today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA’s new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program. View the full release here: https://www.businesswire.com/news/home/20240520770526/en/ This will be an investment of up to $30 million in company-led marketing efforts. Medifast is committed
Medifast To Launch National Marketing Campaign Read More »
May 2, 2024 Management reported that: “We delivered solid performance in the first quarter with end of period subscribers of 4.0 million, improved retention and engagement in our core business, and continued strong growth in our clinical business with 91 thousand end of period clinical subscribers,” said Sima Sistani, the Company’s CEO. “We continue to
Weight Watchers Reports Q1 Results Read More »
April 29, 2024 Management said that: “Our new model is highly differentiated from competitors, with a holistic approach including our habit-based and Coach guided solution along with nutrition products and community support. It will be supported by a reimagined framework for customer acquisition, with a new company-led national marketing campaign, enhancing both awareness of the
Medifast Reports Q1 2024 Results Read More »
April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their
Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »
Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year
Weight Watchers Reports Q4 and 2023 Results Read More »
January 20, 2024 Novo Nordisk and Eli Lilly aren’t the only drug companies active in the prescription diet drugs space. Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related
More Obesity Drugs In The Pipeline Read More »